Ventech

Prewave GmbH is a technology company based in Vienna, Austria, founded in 2017. It specializes in developing a data analytics platform that utilizes machine learning to predict risks in supply chain networks. By analyzing social media data, Prewave's solution monitors and communicates potential supply chain anomalies, allowing businesses to anticipate upcoming risk events and address sustainability challenges. The company's innovative approach enables organizations to enhance their logistics management and mitigate disruptions through timely and informed decision-making.

Prewave GmbH is a technology company based in Vienna, Austria, founded in 2017. It specializes in developing a data analytics platform that utilizes machine learning to predict risks in supply chain networks. By analyzing social media data, Prewave's solution monitors and communicates potential supply chain anomalies, allowing businesses to anticipate upcoming risk events and address sustainability challenges. The company's innovative approach enables organizations to enhance their logistics management and mitigate disruptions through timely and informed decision-making.

Prewave GmbH is a technology company based in Vienna, Austria, founded in 2017. It specializes in developing a data analytics platform that utilizes machine learning to predict risks in supply chain networks. By analyzing social media data, Prewave's solution monitors and communicates potential supply chain anomalies, allowing businesses to anticipate upcoming risk events and address sustainability challenges. The company's innovative approach enables organizations to enhance their logistics management and mitigate disruptions through timely and informed decision-making.

Prewave GmbH is a technology company based in Vienna, Austria, founded in 2017. It specializes in developing a data analytics platform that utilizes machine learning to predict risks in supply chain networks. By analyzing social media data, Prewave's solution monitors and communicates potential supply chain anomalies, allowing businesses to anticipate upcoming risk events and address sustainability challenges. The company's innovative approach enables organizations to enhance their logistics management and mitigate disruptions through timely and informed decision-making.

Themis Bioscience N.V. is a clinical-stage biopharmaceutical company headquartered in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead product candidate, MV-CHIK, has completed Phase II clinical trials for chikungunya treatment. Themis is also engaged in developing vaccines for various health threats, including cancer, Zika virus, Lassa fever, and MERS. Themis leverages its advanced understanding of immune system mechanisms through its innovative vaccine platform, focusing on both emerging and specialized indications. The company has established research collaborations and exclusive licensing agreements to enhance its development capabilities, positioning itself as a strategic partner for leading biotechnology and pharmaceutical firms.

Themis Bioscience N.V. is a clinical-stage biopharmaceutical company headquartered in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead product candidate, MV-CHIK, has completed Phase II clinical trials for chikungunya treatment. Themis is also engaged in developing vaccines for various health threats, including cancer, Zika virus, Lassa fever, and MERS. Themis leverages its advanced understanding of immune system mechanisms through its innovative vaccine platform, focusing on both emerging and specialized indications. The company has established research collaborations and exclusive licensing agreements to enhance its development capabilities, positioning itself as a strategic partner for leading biotechnology and pharmaceutical firms.

Themis Bioscience N.V. is a clinical-stage biopharmaceutical company headquartered in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead product candidate, MV-CHIK, has completed Phase II clinical trials for chikungunya treatment. Themis is also engaged in developing vaccines for various health threats, including cancer, Zika virus, Lassa fever, and MERS. Themis leverages its advanced understanding of immune system mechanisms through its innovative vaccine platform, focusing on both emerging and specialized indications. The company has established research collaborations and exclusive licensing agreements to enhance its development capabilities, positioning itself as a strategic partner for leading biotechnology and pharmaceutical firms.

Asgoodasnew electronics GmbH is a leading provider of refurbished consumer electronics in Europe. The company operates an online retail platform that specializes in selling a variety of electronic gadgets, including cell phones, music players, navigation systems, computers, and smart accessories. Asgoodasnew is also known for its trade-in services, allowing customers in Germany, Austria, Spain, and Poland to easily convert their used electronic devices into cash through its WIRKAUFENS brand and similar services. By offering high-quality refurbished products at lower prices, the company enables consumers to enjoy the experience of purchasing nearly new devices while promoting sustainability in the electronics market.

Asgoodasnew electronics GmbH is a leading provider of refurbished consumer electronics in Europe. The company operates an online retail platform that specializes in selling a variety of electronic gadgets, including cell phones, music players, navigation systems, computers, and smart accessories. Asgoodasnew is also known for its trade-in services, allowing customers in Germany, Austria, Spain, and Poland to easily convert their used electronic devices into cash through its WIRKAUFENS brand and similar services. By offering high-quality refurbished products at lower prices, the company enables consumers to enjoy the experience of purchasing nearly new devices while promoting sustainability in the electronics market.

Themis Bioscience N.V. is a clinical-stage biopharmaceutical company headquartered in Vienna, Austria, specializing in immunomodulation to develop products aimed at protecting against infectious diseases. Founded in 2009, the company’s lead product candidate, MV-CHIK, has completed Phase II clinical trials for chikungunya treatment. Themis is also engaged in developing vaccines for various health threats, including cancer, Zika virus, Lassa fever, and MERS. Themis leverages its advanced understanding of immune system mechanisms through its innovative vaccine platform, focusing on both emerging and specialized indications. The company has established research collaborations and exclusive licensing agreements to enhance its development capabilities, positioning itself as a strategic partner for leading biotechnology and pharmaceutical firms.

Asgoodasnew electronics GmbH is a leading provider of refurbished consumer electronics in Europe. The company operates an online retail platform that specializes in selling a variety of electronic gadgets, including cell phones, music players, navigation systems, computers, and smart accessories. Asgoodasnew is also known for its trade-in services, allowing customers in Germany, Austria, Spain, and Poland to easily convert their used electronic devices into cash through its WIRKAUFENS brand and similar services. By offering high-quality refurbished products at lower prices, the company enables consumers to enjoy the experience of purchasing nearly new devices while promoting sustainability in the electronics market.